Fri, 23rd Oct 2020 19:39
(Recasts with confirmation)
Oct 23 (Reuters) - AstraZeneca Plc has resumed the
U.S. trial of its experimental COVID-19 vaccine after approval
by U.S. regulators, the company said on Friday.
AstraZeneca's U.S. trial was paused on Sept. 6 after
a report of a serious neurological illness, believed to be
transverse myelitis, in a participant in the company's UK trial.
(Reporting by Munsif Vengattil and Carl O'Donnell; Editing by
Anil D'Silva and Rosalba O'Brien)
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:
INGELHEIM, Germany, April 16 (Reuters) - Boehringer Ingelheim on Tuesday overtook Bayer as Germany's largest drugmaker when the unlisted company rep...
(Alliance News) - AstraZeneca PLC on Tuesday said that its immunotherapy Imfinzi showed positive survival rate in people with advanced biliary tract c...
April 12 (Reuters) - The European Union drug regulator found no evidence that a class of diabetes and weight-loss drugs such as Novo Nordisk's hugel...
Astrazeneca (AZN)